1. Home
  2. RYTM vs CNX Comparison

RYTM vs CNX Comparison

Compare RYTM & CNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rhythm Pharmaceuticals Inc.

RYTM

Rhythm Pharmaceuticals Inc.

N/A

Current Price

$97.07

Market Cap

5.8B

Sector

Health Care

ML Signal

N/A

Logo CNX Resources Corporation

CNX

CNX Resources Corporation

HOLD

Current Price

$35.37

Market Cap

5.3B

Sector

Energy

ML Signal

HOLD

Company Overview

Basic Information
Metric
RYTM
CNX
Founded
2008
1860
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Oil & Gas Production
Sector
Health Care
Energy
Exchange
Nasdaq
Nasdaq
Market Cap
5.8B
5.3B
IPO Year
2017
1998

Fundamental Metrics

Financial Performance
Metric
RYTM
CNX
Price
$97.07
$35.37
Analyst Decision
Strong Buy
Sell
Analyst Count
14
7
Target Price
$131.14
$35.71
AVG Volume (30 Days)
421.1K
1.3M
Earning Date
05-05-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
28.34
763.33
EPS
N/A
3.56
Revenue
N/A
$2,239,134,000.00
Revenue This Year
$55.34
N/A
Revenue Next Year
$86.06
$11.14
P/E Ratio
N/A
$10.09
Revenue Growth
N/A
76.76
52 Week Low
$74.50
$29.22
52 Week High
$122.20
$43.62

Technical Indicators

Market Signals
Indicator
RYTM
CNX
Relative Strength Index (RSI) 40.64 42.86
Support Level $99.14 $35.39
Resistance Level $113.04 $37.01
Average True Range (ATR) 3.98 0.88
MACD -0.78 -0.21
Stochastic Oscillator 19.75 4.84

Price Performance

Historical Comparison
RYTM
CNX

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.

About CNX CNX Resources Corporation

CNX Resources Corp is an independent natural gas development, production, midstream and technology company centered in the Appalachian Basin. It is focused on unconventional shale formations, prominently the Marcellus Shale and Utica Shale, in Pennsylvania, Ohio and West Virginia. Additionally, the company operates and develops Coalbed Methane (CBM) properties in Virginia. the company has two reportable segments: Shale and Coalbed Methane. The majority of the company's revenue is derived from the Shale segment.

Share on Social Networks: